Mazdutide, also known as IBI362 and LY3305677, is a peptide that activates the receptors for glucagon and GLP-1. It is developed by Innovent Biologics in China and has been studied by Eli Lilly in the United States.5,8,9 Suzhou government reports describe its approval in China in 2025 for long-term weight management and for type 2 diabetes. These are local-government reports, not the national approval decision or full prescribing information.2,3 It is not FDA-approved. FDA says it has warned companies that illegally sold unapproved drugs containing mazdutide falsely labeled as being for research purposes.4 Large randomized trials in China report weight loss and lower blood sugar, with common gastrointestinal side effects.5,6
Mazdutide at a glance
What it is
A glucagon and GLP-1 receptor agonist developed by Innovent Biologics (IBI362) and studied by Eli Lilly (LY3305677).5,8,9
FDA status
Not FDA-approved. FDA lists mazdutide among unapproved drugs it has warned companies for selling with false research-use labels. Suzhou government reports describe approval in China in 2025.2,3,4
Human evidence
Large randomized trials in China in obesity and type 2 diabetes, and a smaller randomized Phase 2 trial in the United States.5,6,7
Evidence strength
Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned
What is mazdutide?
Mazdutide is a peptide drug developed in China by Innovent Biologics, which ClinicalTrials.gov lists as the sponsor of trials of IBI362, its development code.5,9
Eli Lilly has sponsored trials of the same drug under the code LY3305677, including a completed Phase 2 trial in the United States.7,8
How is mazdutide thought to work?
Mazdutide is designed to activate the receptors for two hormones, glucagon and GLP-1, which are involved in appetite, blood sugar and energy use.5,7
The sources reviewed here do not establish how much each receptor contributes to the effects reported in trials.5,6
What do human studies show?
In GLORY-1, 610 adults in China with overweight or obesity were randomized to mazdutide or placebo. At week 32, average weight change was −10.09% and −12.55% in the two mazdutide groups and +0.45% with placebo. Gastrointestinal events were common.5
In a 28-week trial of 731 adults in China with type 2 diabetes, HbA1c, a measure of long-term blood sugar, fell 0.24 and 0.30 percentage points more with mazdutide than with dulaglutide, and weight fell more. Gastrointestinal events were more frequent with mazdutide.6
In a Phase 2 trial of 179 adults in the United States, estimated weight change at week 32 ranged from −7.3% to −18.1% across mazdutide groups, compared with −0.9% on placebo; 20% of the highest-exposure group stopped because of adverse events.7
What the evidence base contains
Large randomized human trial GLORY-1 (NCT05607680): a randomized, double-blind, placebo-controlled Phase 3 trial in 610 adults in China with overweight or obesity, published in The New England Journal of Medicine.5
Large randomized human trial A 28-week randomized Phase 3 trial in 731 adults in China with type 2 diabetes that compared mazdutide with dulaglutide, published in Nature.6
Controlled human trial A randomized, placebo-controlled Phase 2 trial in 179 adults in the United States with overweight or obesity.7
Not by FDA. FDA’s page on unapproved GLP-1 drugs, current as of October 1, 2026, says it has warned companies that illegally sold unapproved drugs containing mazdutide that were falsely labeled for research purposes or not for human consumption.4
A June 27, 2025 report by the Suzhou Industrial Park market regulator describes Chinese approval of mazdutide for long-term weight management in adults with obesity or overweight.2
A December 19, 2025 Suzhou government report describes approved diabetes and weight-management uses in China.3
These are attributable local-government reports, not China’s national approval decision or complete prescribing information. None of the sources reviewed here reports an approval of mazdutide by FDA or in any jurisdiction outside China.2,3,4
Timeline
Results of the GLORY-1 Phase 3 obesity trial are published in The New England Journal of Medicine.5
A Suzhou Industrial Park regulator report describes Chinese approval of mazdutide for long-term weight management.2
A Suzhou government report describes approved diabetes and weight-management uses in China.3
ClinicalTrials.gov lists Eli Lilly’s Phase 2 trial in the United States as completed.8
FDA’s page on unapproved GLP-1 drugs, which names mazdutide, is updated, as shown by its content-current date.4
What is still unknown?
The exact terms of the Chinese approval, which the local-government reports do not set out in full.2,3
Its long-term effects on heart, kidney and liver outcomes: the published trials measured weight and blood sugar over 28 to 32 weeks, and further trials, including in heart failure, are registered.5,6,10
What is in mazdutide products sold outside approved channels, which FDA describes as unapproved.4
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Mazdutide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Mazdutide are the records PeptideScanner has selected and published, not every registration or paper about Mazdutide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
China: approval reported by local government sources. Large randomized trials in China report weight loss and lower blood sugar. The Chinese approval is reported by local-government sources, not the national approval decision or complete prescribing information. FDA lists mazdutide among unapproved drugs it has warned companies for selling with false research-use labels.↗↗↗↗↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Four selected trials examine mazdutide in adults with obesity or type 2 diabetes in China and the United States. Trial populations, comparators and statistical estimands differ and should not be used to rank results across studies.↗↗↗↗
What the reviewed sources report
Randomized trials reported weight and glucose-control improvements in the studied populations, with gastrointestinal adverse events. These publications do not by themselves establish regulatory status, long-term complications or comparative effectiveness outside their specific designs.↗↗↗↗
What remains unresolved?
How do dated regulatory decisions differ by jurisdiction and indication?↗↗↗↗
What do full reports establish about missing outcomes, uncommon harms and durability?↗↗↗↗
Four selected trials examine mazdutide in adults with obesity or type 2 diabetes in China and the United States. Trial populations, comparators and statistical estimands differ and should not be used to rank results across studies.1234
Bottom line from this bounded source set
Randomized trials reported weight and glucose-control improvements in the studied populations, with gastrointestinal adverse events. These publications do not by themselves establish regulatory status, long-term complications or comparative effectiveness outside their specific designs.1234
610 adults with overweight or obesity participated.1
Outcomes reported
At week 32, intention-to-treat weight changes were −10.09% and −12.55% in active groups versus +0.45% with placebo. Gastrointestinal adverse events were common; adverse-event discontinuation occurred in 1.5%, 0.5% and 1.0%, respectively.1
Limitations
The study concerns its enrolled population and prespecified follow-up. Weight change alone cannot establish cardiovascular benefit or longer-term safety.1
Reviewed study record
Type 2 diabetes: active comparator
Design
Randomized phase 3 comparison with a specified dulaglutide regimen over 28 weeks.2
Population
731 adults in China with type 2 diabetes participated.2
Outcomes reported
Between-group HbA1c differences favored the two mazdutide groups by 0.24 and 0.30 percentage points; reductions in percentage body-weight change were 3.78 and 5.76 percentage points greater than with dulaglutide. Gastrointestinal events were more frequent with mazdutide.2
Limitations
The comparison is specific to the tested regimens and population, not a ranking against all uses of the comparator or other medicines.2
Reviewed study record
Type 2 diabetes: placebo comparison
Design
Randomized, double-blind phase 3 trial with a 24-week primary comparison.3
Population
320 adults in China with type 2 diabetes participated.3
Outcomes reported
HbA1c changes were −1.57 and −2.15 percentage points versus −0.14 with placebo. Gastrointestinal events were common.3
Limitations
The subsequent extension is follow-up of this study, not a separate randomized experiment. Biomarker changes do not establish reduced complications.3
Reviewed study record
US phase 2 obesity trial
Design
Randomized, placebo-controlled phase 2 trial with a week-32 primary endpoint and longer follow-up.4
Population
179 adults with overweight or obesity participated.4
Outcomes reported
The reported hypothetical-estimand weight changes at week 32 were −7.3%, −15.6% and −18.1% versus −0.9%. Adverse events led to discontinuation in 20% of the highest active group.4
Limitations
A hypothetical estimand is not the same as observed outcomes regardless of discontinuation. Population, follow-up and estimand differences prevent direct comparison with GLORY-1.4
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa2411528. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1038/s41586-025-10031-z. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1038/s41586-025-10026-w. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s2213-8587(26)00160-9. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
NCT04904913 describes a 328-participant Chinese study of IBI362 with a 24-week weight endpoint. NCT06124807 describes a separate 179-participant LY3305677 study with a 32-week primary endpoint and 48-week follow-up. Their results are not interchangeable. NCT04904913 ↗NCT06124807 ↗
More findings and the sources behind them
Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.
The later record includes posted weight results
The LY3305677 registry reports modeled mean weight changes of −7.33%, −15.6% and −18.1% across the three active groups versus −0.85% for placebo at week 32. These are changes from baseline in that study, not placebo-adjusted percentages or a cross-drug ranking. NCT06124807 ↗
Longer follow-up involved attrition
The same registry lists 179 participants starting and 128 completing the study. Its repeated-measures estimates should not be mistaken for measurements observed in every participant at every visit; adverse events were among several discontinuation reasons. NCT06124807 ↗
Result availability differs between the two records
The retrieved Chinese phase 2 record has no posted summary-results section, while the LY3305677 record does. Neither registry entry alone establishes the current authorization status in any jurisdiction. NCT04904913 ↗NCT06124807 ↗
What remains to be checked
Reconcile Chinese and international trial families and current jurisdiction-specific regulatory documents.
Appraise original publications and analysis plans, including missing-data assumptions and safety outcomes.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Scoped identity/name search for initial human evidence synthesis; other aliases and preclinical, extension and combination reports require separate eligibility decisions.
51 retrieved · 4 included · 0 excluded · 47 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"mazdutide"[Title/Abstract] OR "IBI362"[Title/Abstract] OR "LY3305677"[Title/Abstract]
Full-text appraisal and screening of unassessed records remain open.
Registry comparison, additional aliases and references, and regulator reconciliation require separate checks.
Showing 25 of 51 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 42628555 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT06124807.
PubMed 41407860 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT05606913.
PubMed 41407859 — include: Selected human report; abstract and record metadata reviewed. Study families: mazdutide-PMID41407859-registry-linkage-unresolved.
PubMed 40421736 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT05607680.
PubMed 42603384 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42410325 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42688617 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42555719 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42535526 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42251768 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42251596 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42251595 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42208956 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42419792 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41948476 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41804840 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41875890 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41820018 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41054801 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41787737 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41901218 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41711462 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41710707 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41389801 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41478576 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
45 retrieved · 0 included · 0 excluded · 45 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 45 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT05793450 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06817356 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07255209 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06184568 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07713992 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06937749 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07135141 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06124807 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02972645 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04773977 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05815680 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04904913 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07797101 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04466904 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07718126 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07517042 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07803705 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07000955 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06931028 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07657676 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07781150 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06884293 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07767552 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05606913 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07809945 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Mazdutide?
China: approval reported by local government sources. Large randomized trials in China report weight loss and lower blood sugar. The Chinese approval is reported by local-government sources, not the national approval decision or complete prescribing information. FDA lists mazdutide among unapproved drugs it has warned companies for selling with false research-use labels.↗↗↗↗↗
The cited status sources were checked through September 15, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Status at observationNot yet recruiting 5Recruiting 4Active, not recruiting 2Completed 2
A phase value is unavailable here for 4 selected records; this is not counted as “no phase.”
A status value is unavailable here for 4 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
0 of 5 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Bibliography fields unavailable here for 5 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
22
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 22 dated records
We added a plain-language reader guide with cited answers, published trial results from our human evidence review, ClinicalTrials.gov records naming Innovent and Eli Lilly, and FDA’s current page on unapproved GLP-1 drugs, which names mazdutide. The status line keeps its cited China-only wording.
PeptideScanner retained ClinicalTrials.gov record NCT06862908 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT06937749 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was mazdutide.
Selected records span March 7, 2024 to November 12, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PeptideScanner retained ClinicalTrials.gov record NCT07517042 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was mazdutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07775846 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was mazdutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07924553 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was mazdutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07897305 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was mazdutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06937749 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was mazdutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07843862 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was mazdutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06862908 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was mazdutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07803705 at 2026-09-09T19:17:17.113Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was mazdutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07083154 at 2026-09-09T19:17:17.091Z. Its registry update date was 2026-09-02, and PeptideScanner's reviewed identity mapping was mazdutide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42251596 at 2026-08-10T10:49:10.669Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2026-06-07. PeptideScanner associated this retained record with the identity slug mazdutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained ClinicalTrials.gov record NCT07718126 at 2026-08-10T18:10:03.957Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was mazdutide.↗